Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by RPINVESTOR1on Mar 18, 2024 6:45pm
78 Views
Post# 35939341

RE:RE:RE:RepliCel Life signs LOI with CEO for asset purchase

RE:RE:RE:RepliCel Life signs LOI with CEO for asset purchaseHi Metzger:-

Unless this deal is (1) fair to all shareholders - large and small - and is (2) explained in such a way that a 10 year old can understand it, I will automatically vote 'no.' Andrew Schutte stands to be the big loser if Replicel goes bankrupt. I do not see why he should be the big winner, at the expense of everyone else, by taking the Company private. 

I must admit that I fell off the Andrew Schutte bandwagon quite a long time ago. My reasons for this change in thinking include the following:-

1. Investing in private placements when the share price was depressed and sweetening the deal with generous warrants. 
2. Failing to communicate with shareholders - despite answering his phone! - and hiding behind excuses such as the lawyers are handling some  confidential matters or we are speaking with potential partners.
3. When they met with Shiseido representatives in Japan he stated to them that they were told that Replicel would only make a deal (sale???) if it was in the best interests of Replicel. He never provided us with any additional details on any offer.
4. He did not provide a detailed explanation as to why Replicel was so optimistic about a favourable outcome in the arbitration and why the arbitrator sided with Shiseido's position. He only said that Replicel had lost the arbitration decision.
5. The press release states that the maximum a small shareholder can receive is $2.00? Looks like a potential win for Andrew Schutte.

Metzger, These are just some of my concerns. Also, for all we know Andrew Schutte could have a secret deal with Shiseido that will only occur at some time in the future. I guess we all have to make individual calls on this propsed deal. I however do not have faith in this offer.     
<< Previous
Bullboard Posts
Next >>